A1502, the “Patient and Provider Protection Act,” overhauls New Jersey’s pharmacy benefits manager (PBM) rules. The bill rewrites definitions in the State’s PBM law to define PBM compensation as a fee for services that cannot exceed the value of the services actually performed, and it expands the list of PBM services to include negotiating rebates and discounts, claims processing, utilization review, prior authorization, network contracting, data management, and related administrative functions. It also adds legislative findings asserting that PBM compensation structures tied to list prices, rebates, and affiliated pharmacy profits can create conflicts of interest and raise prescription drug costs.
The bill imposes several substantive restrictions on PBMs and related contracts. It bars PBM compensation from being directly or indirectly tied to drug acquisition cost, savings, rebates, premiums, deductibles, or other patient cost-sharing. It requires annual certification of compliance, disclosure of certain broker fees, and additional documentation for rate filings and loss-ratio calculations. It also applies these rules to the State Health Benefits Program and School Employees’ Health Benefits Program, and it expands the definition of health benefits plan to include the State Medicaid program, the State Health Benefits Program, and the School Employees’ Health Benefits Program.
A1502 further adds fiduciary-duty language, requiring PBMs to act in the best interests of carriers and certain State programs, while expressly stating that this does not create a private cause of action for subscribers or covered persons. It prohibits misleading marketing to steer patients to contracted pharmacies, invalidates manufacturer agreements that condition rebates on excluding generic drugs from coverage, and presumes PBM-pharmacy contracts are contracts of adhesion in disputes. The bill also establishes reimbursement standards tied to NADAC plus the State Medicaid professional dispensing fee, prohibits differential payment pricing based on ownership or affiliation, protects pharmacy participation rights, and restricts requirements or incentives that steer patients to PBM-owned or affiliated mail-order or specialty pharmacies.
The bill’s impact on state law would be significant for insurers, PBMs, pharmacies, and public health plans. It would strengthen state oversight of PBM pricing and contracting practices, limit spread-pricing- and rebate-based compensation models, and extend PBM regulation to major public coverage programs that were previously excluded from some provisions. It would also likely affect how carriers file rates and calculate loss ratios, how PBMs structure contracts with manufacturers and pharmacies, and how independent and affiliated pharmacies are reimbursed and included in networks.
The general sentiment reflected in the bill text and committee action is strongly supportive of tighter PBM regulation. The Assembly Financial Institutions and Insurance Committee reported the substitute unanimously, 10-0, indicating broad committee backing. The findings section frames the bill as a consumer- and pharmacy-protection measure aimed at lowering drug costs, improving transparency, and reducing conflicts of interest in the prescription drug supply chain.
The main points of contention are likely to center on the bill’s limits on PBM business models and its expansion of state oversight. PBMs and affiliated insurers may object to the fiduciary-duty language, the ban on compensation tied to rebates or drug prices, the reimbursement floor tied to NADAC plus dispensing fees, and the restrictions on affiliated pharmacy steering and differential pricing. Pharmacies and plan sponsors may support the bill’s transparency and access provisions, but the adhesion-contract presumption and the broad regulatory reach into public programs could still raise implementation and compliance concerns.
The bill would amend and expand New Jersey’s PBM statutes in P.L.2015, c.179 and related provisions to require fee-based, value-limited PBM compensation; prohibit price- and rebate-based compensation structures; impose disclosure, certification, and filing requirements; and extend key rules to Medicaid, the State Health Benefits Program, and the School Employees’ Health Benefits Program. It would also regulate PBM-pharmacy reimbursement, network access, and patient steering practices, affecting carriers, PBMs, manufacturers, pharmacies, and public benefit programs.
The available legislative history suggests favorable sentiment toward the bill’s goals of lowering drug costs and curbing PBM conflicts of interest. The Assembly Financial Institutions and Insurance Committee reported the substitute 10-0, indicating unanimous committee support. The bill’s findings also show a strong policy consensus in favor of transparency, fiduciary alignment, and pharmacy access protections.
Likely areas of contention include the bill’s prohibition on compensation tied to rebates, list prices, or utilization; the fiduciary-duty requirement for PBMs; the reimbursement standard based on NADAC plus a dispensing fee; and the limits on affiliated pharmacy steering and differential pricing. PBMs and vertically integrated insurers may argue these provisions interfere with contracting and business models, while independent pharmacies and consumer advocates are likely to support them as necessary to prevent steering, spread pricing, and under-reimbursement.